Table 1.
Patient Characteristics: Total cohort includes all patients ≥18 years with prostate cancer (N=328,989) and study cohort includes patients with prostate cancer who received any of the six treatments and were continuously enrolled for ≥ 180 days before receipt of their first treatment (n = 5,575) over the study period years 2010 through mid-2016
| Total Cohort (N=328,989) | Final Cohort (n=5,575) | |||
|---|---|---|---|---|
| Variable | Mean [Range]/Count (%) | Mean range/Count (%) | ||
| Age | 71.44 | [18,90] | 73.62 | [32,90] |
| Race | ||||
| White | 223,035 | (67.8) | 3,888 | (69.7) |
| Black | 37,567 | (11.4) | 737 | (13.2) |
| Asian | 6,239 | (1.9) | 108 | (1.9) |
| Hispanic | 23,091 | (7.0) | 410 | (7.4) |
| Unknown | 39,057 | (11.9) | 432 | (7.8) |
| Education level | ||||
| Less than 12th Grade | 1,530 | (0.5) | 37 | (0.7) |
| High School Diploma | 89,140 | (27.1) | 1,621 | (29.1) |
| Less than Bachelor Degree | 162,252 | (49.3) | 2,858 | (51.3) |
| Bachelor Degree Plus | 45,880 | (13.9) | 785 | (14.1) |
| Unknown | 30,187 | (9.2) | 274 | (4.9) |
| Household income range | ||||
| <$50,000 | 98,244 | (29.9) | 1,985 | (35.6) |
| $50,000-$99,000 | 96,987 | (29.5) | 1,721 | (30.9) |
| >$99,000 | 76,551 | (23.3) | 1,091 | (19.6) |
| Unknown | 57,207 | (17.4) | 778 | (14.0) |
| Net worth | ||||
| <$25,000 | 18,347 | (5.6) | 334 | (6.0) |
| $25,000-$149,000 | 47,045 | (14.3) | 891 | (16.0) |
| $150,000-$249,000 | 42,972 | (13.1) | 773 | (13.9) |
| $250,000-$499,000 | 81,771 | (24.9) | 1,393 | (25.0) |
| >$500,000 | 85,002 | (25.8) | 1,454 | (26.1) |
| Unknown | 53,852 | (16.4) | 730 | (13.1) |
| Geographic Region* | ||||
| South Atlantic | 89,340 | (27.2) | 1,291 | (23.1) |
| New England | 17,999 | (5.5) | 285 | (5.1) |
| Middle Atlantic | 32,045 | (9.7) | 440 | (7.9) |
| East North Central | 46,568 | (14.2) | 806 | (14.5) |
| East South Central | 11,747 | (3.6) | 202 | (3.6) |
| West North Central | 32,548 | (9.9) | 604 | (10.8) |
| West South Central | 32,775 | (10.0) | 539 | (9.7) |
| Mountain | 31,429 | (9.6) | 609 | (10.9) |
| Pacific | 33,078 | (10.1) | 771 | (13.8) |
| Unknown | 1,460 | (0.4) | 28 | (0.5) |
| Metastatic | ||||
| Yes | 28,451 | (8.6) | 4,890 | (87.7) |
| No | 300,538 | (91.4) | 685 | (12.3) |
| Year | ||||
| 2010 | 97,410 | (29.6) | 2,365 | (42.4) |
| 2011 | 101,968 | (31.0) | 2,743 | (49.2) |
| 2012 | 110,243 | (33.5) | 3,071 | (55.1) |
| 2013 | 117,544 | (35.7) | 3,237 | (58.1) |
| 2014 | 115,297 | (35.0) | 3,132 | (56.2) |
| 2015 | 122,555 | (37.3) | 2,872 | (51.6) |
| 2016 | 99,292 | (30.2) | 1,992 | (35.7) |
| Comorbid condition | ||||
| Hypertension | 223,777 | (68.0) | 3,842 | (68.9) |
| Diabetes | 94,275 | (28.7) | 1,584 | (28.4) |
| Arrhythmia | 71,897 | (21.9) | 1,151 | (20.4) |
| Congestive heart failure | 39,342 | (12.0) | 597 | (10.7) |
| Osteoporosis | 13,374 | (4.1) | 385 | (6.9) |
OR, Odds Ratio; CI, Confidence Interval
Geographic region:
New England: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont
Middle Atlantic: New Jersey, New York, Pennsylvania
East North Central: Illinois, Indiana, Michigan, Ohio, Wisconsin
West North Central: Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South Dakota
South Atlantic: Delaware, Washington D.C., Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia
East South Central: Alabama, Kentucky, Mississippi, Tennessee
West South Central: Arkansas, Louisiana, Oklahoma, and Texas
Mountain: Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming
Pacific: Alaska, California, Hawaii, Oregon, Washington